Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
|
|
- Hilary Sullivan
- 6 years ago
- Views:
Transcription
1 Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center San Antonio, Texas
2 Concepts Using baseline predictors of response Utilizing on-treatment viral response and knowing when to quit Treating the most difficult patient population: the cirrhotic Getting the patient through treatment: On treatment management
3 Case 1: Treatment Failure Patient A 54 yo male was previously treated with pegylated interferon alfa-2b and ribavirin in 27 4 log decline by week 24, but never became undetectable through 48 weeks of therapy No week 12 data available Past medical history includes mild hypertension and hyperlipidemia, but neither have required therapy
4 Case 1: Labs and Imaging Viral Data and CBC HCV Genotype1a 3.4 million IU/mL WBC: 3,9/ L HB 14.6 g/dl Liver Panel and Ultrasound Total bilirubin.8 mg/dl ALT 118 IU/L; AST 97 IU/L Albumin 3.6 g/dl -Fetoprotein 2.4 ng/ml Platelets 135,/ L Ultrasound: 1 cm liver, spleen 13 cm ALT = alanine aminotransferase; AST = aspartate aminotransferase.
5 Concepts Using baseline predictors of response
6 Baseline Predictors Can Help Guide Us Past treatment experience Subtype Viral load Fibrosis Ethnicity IL-28B status
7 Baseline Predictors of SVR Vary in Naïve Versus Treatment Experienced Poordad F, et al. Gastroenterology 212;143(3):68-618
8 SVR (%) SVR Rates With BOC or TVR + PR According to Treatment History 1 8 Relapsers Naive Partial Responders Null Responders Poordad F, et al. N Engl J Med. 211;364: Jacobson IM, et al. N Engl J Med. 211;364: Bacon BR, et al. N Engl J Med. 211;364: Zeuzem S, et al. N Engl J Med. 211;364: Bronowicki JP, et al. EASL 212. Abstract 11.
9 SVR (%) REALIZE: SVR by Baseline Fibrosis Stage and Prior Response (TVR) 1 8 Prior Relapsers Prior Partial Responders Prior Null Responders Pooled T12/PR48 PBO/PR n/n= 144/167 12/38 53/62 2/15 48/57 2/15 34/47 3/17 1/18 /5 11/32 1/5 24/59 1/18 15/38 /9 7/5 1/1 Stage No, minimal or portal fibrosis Bridging fibrosis Cirrhosis No, minimal or portal fibrosis Bridging fibrosis Cirrhosis No, minimal or portal fibrosis Bridging fibrosis Cirrhosis Zeuzem, et al. N Engl J Med. 211 Jun 23;364(25):
10 Does IL-28B Help?
11 SVR by IL-28B Genotype for (A) Previously Untreated Patients and (B) Previous Treatment-Failure Patients Poordad F, et al. Gastroenterology 212;143(3):68-618
12 Case 1: Week 4 PCR was <1 log decline Started on PegIFN and RBV At week 4, the PCR is 89, IU/mL This means the patient has poor IFN response What are his chances of responding?
13 Concepts Utilizing on-treatment viral response and knowing when to quit
14 SVR % Comparison of Lead-in Arms of Treatment-Experienced Trials REALIZE (TVR) <1 log Decline 1 log Decline 76 RESPOND 2* (BOC) * Pooled data from Arm 2 (RGT) and Arm 3 Foster GR, et al. EASL 211. Abstract 6. Bacon BR, et al. NEJM. 211;364:
15 % of Patients PROVIDE Final Results: SVR Rates by Prior Treatment Response All patients treated with BOC + PEG/RBV 41 All includes: Nulls, Partials, Relapsers and Other Boceprevir is now labeled for null responders Vierling, et al. DDW 213 Nulls Partials Relapsers All 67 SVR (FAS) /49 57/85 27/28 16/164
16 Early Interferon Response (Lead-In) Further Defines Likelihood of Success for Non-CC Patients SPRINT-2 and RESPOND-2 Combined PR48 BOC RGT BOC/PR <1 log 1log <1log 1log <1log 1log CC CT TT Poordad F, et al. Gastroenterology 212;143(3):68-618
17 Futility Rules for BOC or TVR + PegIFN/RBV in Treatment-Experienced Patients Recommendation: All therapy should be discontinued in patients with the following: BOC [1,2] Time Point Criteria Action Wk 12 HCV RNA 1 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue all therapy TVR [2,3] Time Point Criteria Action Wk 4 or 12 HCV RNA >1 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue pegifn/rbv Assay should have a lower limit of HCV RNA quantification of 25 IU/mL and a limit of HCV RNA detection of approximately 1-15 IU/mL. 1. Boceprevir [package insert]. 2. Ghany MG, et al. Hepatology. 211;54: Telaprevir [package insert].
18 % SVR SVR in Poor IFN Responders Based on TW8 Response (Log Decline in VL Compared to BL VL) (BOC Arms Combined) < > < >5 < > RESPOND-2 SPRINT-2 Combined Studies Poordad F, et al. Gastroenterology 212;143(3):68-618
19 Potential Arguments for a Lead-in PEG-IFN + RBV Dosing Period Predict interferon responsiveness Can stop therapy and avoid side effects in face of likely futility Maintain patient s eligibility for trials of new direct-acting antivirals when few PI failure studies are available Assess hematologic response to pegifn/rbv therapy and make needed dose adjustments before starting PI Modified from Kwo PY, et al. Lancet 21;376(9742):75-16.
20 Concepts Treating the most difficult patient population: the cirrhotic
21 Meta-Analysis of Cirrhotic Patients in Boceprevir Trials Sources of data SPRINT-2 RESPOND-2 PEGASYS study EPO study Interim data from PROVIDE Total of 212 F4 patients (18 on BOC/PR, 32 on PR) Aims Dx by central reading of liver biopsies To consolidate results from SPRINT2/RESPOND2 in a larger population of patients To provide predictors of SVR by multiple logistic regression analysis To evaluate risk of severe AEs, as suggested by real-life study (CUPIC) To develop newer reliable futility which will enable sparing cost and risk of therapy To assess whether short treatment duration (i.e. 36 weeks) might be used in a subset of patients Vierling JM, et al. EASL 213
22 SVR % Overall SVR by F3 and F4 1 BOC PR PR /18 6/32 58/17 6/22 F4 F3 Vierling JM, et al. EASL 213
23 SVR (%, 95% CI) SVR According To Treatment Week 4 Virologic Response In F3 And F log HCV-RNA decline at TW4 <1 log HCV-RNA decline at TW /7 1/35 85/128 1/48 F3 F4 Vierling JM, et al. EASL 213
24 Real World Cirrhotics: CUPIC Patient Baseline Demographics Characteristic Telaprevir N=295 Boceprevir N=19 Child-Pugh score A/B, n (%)* 28 (95) / 6 (2) 177 (93) /1 (1) MELD score, mean (range) 8.1 (6-22) 8.1 (6-28) Prothrombin time ratio, mean % (range) 86 (27 1) 87 (23 1) Serum albumin (g/l), mean (range) 4. ( ) 4.7 ( ) Total bilirubin (μmol/l), mean (range) 15.5 (4. 73.) 15.2 (4. 78.) Hemoglobin (g/dl), mean (range) 14.5 ( ) 14.8 ( ) Neutrophils (1 9 /mm 3 ), mean (range) 3.3 (.8-8.5) 3.2 (.5-8.5) Platelet count (1 3 /mm 3 ), mean (range) 151 (18 64) 144 (34 346) Esophageal varices, n (%) 51/145 (35.2) 37/97 (38.1) * Missing data : 21 Fontaine H, et al. 48th EASL; Amsterdam, Netherlands; April 24-28, 213. Abst. 6
25 Patients with undetectable HCV RNA (Percentage) CUPIC Virological response (ITT): SVR12 1 TELAPREVIR 1 BOCEPREVIR % 79% 81% 77 % 68 % 56% % 6 51% % 67% 57% 4% 41% % W4 W8 W12 W16 W24 W48 W W4 W8 W12 W16 W24 W48 W6 Fontaine H, et al. 48th EASL; Amsterdam, Netherlands; April 24-28, 213. Abst. 6
26 CUPIC: Safety Findings Patients, n (% patients with at least one event) Serious adverse events (SAEs) Telaprevir n=295 Boceprevir n= in 16 patients (54.2%) 321 in 97 patients (51.%) Premature discontinuation / due to SAEs 139 (47.1%) / 63 (21.3%) 8 (42.1%) / 27 (14.2%) Death 7 (2.4%) 3 (1.6%) Infection (Grade 3/4) 27 (9.1%) 8 (4.2%) Hepatic decompensation (Grade 3/4 ) 15 (5.1%) 9 (4.7%) Anemia (Grade 3/4: Hb<8 g/dl) 38 (12.9%) 19 (1%) Rash (Grade 3/SCAR) 16 (5.4%) / 2 (.6%) 2 (1.%) / EPO use / blood transfusion 168 (57%) / 53 (18%) 119 (62.6%) / 26 (13.7%) GCSF use 8 (2.7%) 13 (6.8%) TPO use 6 (2%) 3 (1.6%) SCAR: severe cutaneous adverse reaction Fontaine H, et al. 48th EASL; Amsterdam, Netherlands; April 24-28, 213. Abst. 6
27 CUPIC: Predictors of Severe Anemia Multivariate analysis: Baseline factors related to anemia <8 g/dl or blood transfusion Predictors OR 95%CI p-value Gender: Female No lead-in phase Age 65 years Hemoglobin level 12 g/dl for female 13 g/dl for male <.1 Hezode, C, et al. 63rd AASLD; Boston, MA; November 9-13, 212. Abst. 51.
28 CUPIC: Risk of Occurrence of Death or Severe Complications Factors Platelet count >1,/mm 3 Platelet count 1,/mm 3 Albumin 3.5 mg/l 3.4% (1/298) 4.3% (3/69) Albumin <3.5 mg/l 7.1% (2/28) 44.1% (15/34) Hezode, C, et al. 63rd AASLD; Boston, MA; November 9-13, 212. Abst. 51.
29 Concepts Getting the patient through treatment: On treatment management of anemia
30 SVR Rates Similar Between Groups Regardless of Viremia Status at Start of Anemia Management SVR (%; 95% CIs) All patients treated with BOC + PEG/RBV RBV DR EPO RBV DR EPO Undetectable Undetectable Detectable Detectable Poordad F et al, Abstract 154, AASLD 212
31 SVR (%, 95% CI) SVR Rates by Lowest RBV Dose Received for 14 Days* Lowest RBV Dose (mg/day) for 14 days *The lowest RBV dose (mg/day) received for at least 14 days during the treatment period based on information in patient diaries. Poordad F et al, Abstract 154, AASLD
32 SVR (%) SVR by Percent Total RBV Dose Received in Patients Who Received 8% of Treatment Duration <5 5<6 6<7 7<8 8 % Total RBV Dose Received vs. Assigned Total RBV Dose* *Assigned Total RBV Dose = Per-protocol assigned total RBV dose for the entire treatment period Poordad F et al, Abstract 154, AASLD
33 Summary Treat previous relapsers since likelihood of SVR is very high Consider baseline predictors of response Cirrhosis Genotype 1b Non-black IL-28B CC variants Use on-treatment viral kinetics to predict outcome and also to stop therapy early when futile 4 week lead in (boceprevir and telaprevir) Week 8 log decline in poor interferon responders (boceprevir) Week 12 futility rule (boceprevir and telaprevir) Manage anemia aggressively with RBV dose reduction Weekly CBC in cirrhotics Can hold RBV if necessary Use secondary anemia management when needed
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationEfficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationBOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationUpdates on Current Status of HCV Therapy
Updates on Current Status of HCV Therapy K. Rajender Reddy, MD Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology and Medical Director of Liver Transplantation University of
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationBackground: Narlaprevir (SCH )
Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationHIV HCV Co Infection Case: The Agnostic Radiologist
HIV HCV Co Infection Case: The Agnostic Radiologist Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationHCV treament with DAA Side effects: Anemia, Skin Manifestations Pr Patrice CACOUB
HCV treament with DAA Side effects: Anemia, Skin Manifestations Pr Patrice CACOUB Service de Médecine Interne, CNRS UMR 7211, INSERM UMR 959 Université Pierre et Marie Curie Centre National de Référence
More informationThe Scope of The Problem US Prevalence: 1.8% are chronically infected with Hepatitis C virus (HCV)
The Scope of The Problem US Prevalence: 1.8% are chronically infected with Hepatitis C virus (HCV) World Health Organization. Hepatitis C: Fact Sheet. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationReal-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C
Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C Prof. Gamal Esmat Prof. Hepatology & Vice President of Cairo
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationTreatment of chronic hepatitis C in drug-naïve patients
Treatment of chronic hepatitis C in drug-naïve patients 8th International Workshop on HIV & Hepatitis Co-infection Madrid, 31. May 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationHepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid
Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid Caveats on hepatitis C therapy decision making We treat persons with a liver. They
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationSURVEYOR-II Part 2 Study Design
HIGH SVR RATES WITH + CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION A.J. Muir, S. Strasser, S. Wang, S. Shafran, M. Bonacini, P. Kwo, D. Wyles, E. Gane, S.S. Lovell,
More information